BioStock: New results open up for a broader indication for Respiratorius

Lund-based drug developer Respiratorius continues to advance the project with drug candidate VAL001. The company recently announced positive preclinical results that showed that VAL001 may have potential even for patients with a more severe type of diffuse large B-cell lymphoma. Now there are signs that the candidate could potentially also be used in the treatment of patients who relapse into disease.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/new-results-open-up-for-a-broader-indication-for-respiratorius

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se